These antibodies are used to treat metastatic (spread) breast cancer. It is effective against tumors that overexpress the HER2/neu protein.
This report aims to provide a comprehensive presentation of the global market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer. This report contains market size and forecasts of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in global, including the following market information:
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Pertuzumab Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer include Roche, BOC Sciences, LGM Pharma, Biotechnica Pharma Global, KinBio and Merck, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Segment Percentages, by Type, 2022 (%)
Pertuzumab
Trastuzumab
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Segment Percentages, by Application, 2022 (%)
Combination Therapy
Mono Therapy
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
BOC Sciences
LGM Pharma
Biotechnica Pharma Global
KinBio
Merck
Outline of Major Chapters:
Chapter 1: Introduces the definition of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, market overview.
Chapter 2: Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size in revenue.
Chapter 3: Detailed analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Overall Market Size
2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size: 2022 VS 2029
2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players in Global Market
3.2 Top Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Companies Ranked by Revenue
3.3 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Companies
3.4 Top 3 and Top 5 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players in Global Market
3.6.1 List of Global Tier 1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Markets, 2022 & 2029
4.1.2 Pertuzumab
4.1.3 Trastuzumab
4.2 By Type - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue & Forecasts
4.2.1 By Type - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2023
4.2.2 By Type - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2024-2029
4.2.3 By Type - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2022 & 2029
5.1.2 Combination Therapy
5.1.3 Mono Therapy
5.2 By Application - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue & Forecasts
5.2.1 By Application - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2023
5.2.2 By Application - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2024-2029
5.2.3 By Application - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2022 & 2029
6.2 By Region - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue & Forecasts
6.2.1 By Region - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2023
6.2.2 By Region - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2024-2029
6.2.3 By Region - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2029
6.3.2 US Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.3.3 Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.3.4 Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2029
6.4.2 Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.4.3 France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.4.4 U.K. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.4.5 Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.4.6 Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.4.8 Benelux Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2029
6.5.2 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.5.3 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.5.4 South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.5.6 India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2029
6.6.2 Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.6.3 Argentina Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2029
6.7.2 Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.7.3 Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
6.7.5 UAE Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, 2018-2029
7 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Major Product Offerings
7.1.4 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 BOC Sciences
7.2.1 BOC Sciences Company Summary
7.2.2 BOC Sciences Business Overview
7.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Major Product Offerings
7.2.4 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global Market (2018-2023)
7.2.5 BOC Sciences Key News & Latest Developments
7.3 LGM Pharma
7.3.1 LGM Pharma Company Summary
7.3.2 LGM Pharma Business Overview
7.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Major Product Offerings
7.3.4 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global Market (2018-2023)
7.3.5 LGM Pharma Key News & Latest Developments
7.4 Biotechnica Pharma Global
7.4.1 Biotechnica Pharma Global Company Summary
7.4.2 Biotechnica Pharma Global Business Overview
7.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Major Product Offerings
7.4.4 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global Market (2018-2023)
7.4.5 Biotechnica Pharma Global Key News & Latest Developments
7.5 KinBio
7.5.1 KinBio Company Summary
7.5.2 KinBio Business Overview
7.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Major Product Offerings
7.5.4 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global Market (2018-2023)
7.5.5 KinBio Key News & Latest Developments
7.6 Merck
7.6.1 Merck Company Summary
7.6.2 Merck Business Overview
7.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Major Product Offerings
7.6.4 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global Market (2018-2023)
7.6.5 Merck Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Opportunities & Trends in Global Market
Table 2. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers in Global Market
Table 3. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints in Global Market
Table 4. Key Players of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in Global Market
Table 5. Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Type
Table 9. List of Global Tier 1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 30. Roche Company Summary
Table 31. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offerings
Table 32. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Roche Key News & Latest Developments
Table 34. BOC Sciences Company Summary
Table 35. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offerings
Table 36. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. BOC Sciences Key News & Latest Developments
Table 38. LGM Pharma Company Summary
Table 39. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offerings
Table 40. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. LGM Pharma Key News & Latest Developments
Table 42. Biotechnica Pharma Global Company Summary
Table 43. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offerings
Table 44. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Biotechnica Pharma Global Key News & Latest Developments
Table 46. KinBio Company Summary
Table 47. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offerings
Table 48. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 49. KinBio Key News & Latest Developments
Table 50. Merck Company Summary
Table 51. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offerings
Table 52. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 53. Merck Key News & Latest Developments
List of Figures
Figure 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Segment by Type in 2022
Figure 2. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Segment by Application in 2022
Figure 3. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in 2022
Figure 8. By Type - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 9. By Application - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 10. By Type - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 12. By Application - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 14. By Region - Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 15. By Country - North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 16. US Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 20. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 21. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 28. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 32. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 34. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share, 2018-2029
Figure 37. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 41. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
